Regeneron and Novartis on Innovating to Accommodate Growing Pipelines
Panelists from Regeneron and Novartis discuss how the implementation of artificial intelligence, real-world evidence, diversity, equity and inclusion, and decentralized clinical trials impact clinical trial design.
![Regeneron and Novartis on Innovating to Accommodate Growing Pipelines](https://d38uvx7mib76ry.cloudfront.net/public/images/Jh9nGw24ptkUYuJaKuvVVtqfg99hiCTIGWVzWCkx.png)
Summary:
In this podcast, you will hear a panel discussion from the 2022 DPHARM conference on examining how modernizations like the implementation of AI/ML, RWE, DE&I, DCTs impacted the need for more flexibility clinical trial design, and building protocols in tandem with study design and re-envisioning methods to execute trials.
For more information on DPHARM: Disruptive Innovations to Modernize Clinical Research, visit DPHARMconference.com.
Related Podcasts
View All![Preferences in Decentralization and Digitalization of Pediatric Clinical Trials: Case Study](https://d38uvx7mib76ry.cloudfront.net/public/images/KRCjqX07kLJ0SL4dvkzKWHu2k4zTF6KJRldzVB8V.png)
Preferences in Decentralization and Digitalization of Pediatric Clinical Trials: Case Study
![Optimizing the Integration of Mobile, Patient-Facing Technologies in Clinical Trials for Accessibility and Flexibility](https://d38uvx7mib76ry.cloudfront.net/public/images/QvF6WsV1McmJEIl7xaQnVJszPxkclRJpeMahwZtQ.png)
Optimizing the Integration of Mobile, Patient-Facing Technologies in Clinical Trials for Accessibility and Flexibility
![Delivering Exceptional Clinical Trial Experiences for Patients](https://d38uvx7mib76ry.cloudfront.net/public/images/T3xgX7ADqfhMees6nwfMIA39eY0LVFEDaBMa04sd.png)
Delivering Exceptional Clinical Trial Experiences for Patients
![Measuring the Value of DCTs and Hybrid Models for Ultimate Trial Success](https://d38uvx7mib76ry.cloudfront.net/public/images/NpWjk0KiWqAvOIgFpl1XXajvZj7XbHjyVuXzwZNv.png)